Shopping Cart 0
Cart Subtotal
AED 0

Infant Bacterial Therapeutics AB (IBT B) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 1101

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 2202

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 3303

Details

Summary

Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacillus reuteri, co-evolved human bacterial strain derived from human breast milk, used for the prevention of Necrotizing enterocolitis (NEC); and IBP-1016, a drug candidate used for the treatment of gastroschisis, a severe disease in infants. The company develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal injury, necrosis, perforation in the intestinal tracts of infants and death. It operates through a network of neonatologists and research groups. IBT is headquartered in Stockholm City, Sweden.

Infant Bacterial Therapeutics AB Key Recent Developments

Feb 05,2019: Infant Bacterial Therapeutics names Anna Olsson as Director of Clinical Development

Nov 21,2018: The Phase 3 study protocol is modified after IBT's meeting with the FDA

Nov 14,2018: Infant Bacterial Therapeutics interim management statement, January 1-September 30, 2018

Sep 10,2018: TOPC : Nasdaq Stockholm Welcomes Infant Bacterial Therapeutics to the Main Market[Newswire : FS-GNW RSS]

Aug 16,2018: Infant Bacterial Therapeutics interim management statement, January 1-June 30, 2018

This comprehensive SWOT profile of Infant Bacterial Therapeutics AB provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData's 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Infant Bacterial Therapeutics AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

READ MORE

Table Of Content

Scope

Table of Contents

Section 1-About the Company

Infant Bacterial Therapeutics AB-Key Information

Infant Bacterial Therapeutics AB-Overview

Infant Bacterial Therapeutics AB-Key Employees

Infant Bacterial Therapeutics AB-Key Employee Biographies

Infant Bacterial Therapeutics AB-Key Operational Heads

Infant Bacterial Therapeutics AB-Major Products and Services

Infant Bacterial Therapeutics AB-History

Infant Bacterial Therapeutics AB-Company Statement

Infant Bacterial Therapeutics AB-Locations And Subsidiaries

Infant Bacterial Therapeutics AB-Key Manufacturing facilities

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Infant Bacterial Therapeutics AB-Business Description

Infant Bacterial Therapeutics AB-Corporate Strategy

Infant Bacterial Therapeutics AB-SWOT Analysis

SWOT Analysis-Overview

Infant Bacterial Therapeutics AB-Strengths

Infant Bacterial Therapeutics AB-Weaknesses

Infant Bacterial Therapeutics AB-Opportunities

Infant Bacterial Therapeutics AB-Threats

Infant Bacterial Therapeutics AB-Key Competitors

Section 3-Company Financial Performance Charts

Infant Bacterial Therapeutics AB-Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Appendix

Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Note*: Some sections may be missing if data is unavailable for the company


List Of Figure

List of Figures

Infant Bacterial Therapeutics AB, Performance Chart

Infant Bacterial Therapeutics AB, Ratio Charts


List Of Table

List of Tables

Infant Bacterial Therapeutics AB, Key Information

Infant Bacterial Therapeutics AB, Key Ratios

Infant Bacterial Therapeutics AB, Share Data

Infant Bacterial Therapeutics AB, Major Products and Services

Infant Bacterial Therapeutics AB, History

Infant Bacterial Therapeutics AB, Key Employees

Infant Bacterial Therapeutics AB, Key Employee Biographies

Infant Bacterial Therapeutics AB, Key Operational Heads

Infant Bacterial Therapeutics AB, Other Locations

Infant Bacterial Therapeutics AB, Subsidiaries

Infant Bacterial Therapeutics AB, Key Manufacturing facilities

Infant Bacterial Therapeutics AB, Key Competitors

Infant Bacterial Therapeutics AB, SWOT Analysis

Infant Bacterial Therapeutics AB, Ratios based on current share price

Infant Bacterial Therapeutics AB, Annual Ratios

Infant Bacterial Therapeutics AB, Interim Ratios

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Infant Bacterial Therapeutics AB, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History, Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

Company Profile

Company Profile Title

Summary

Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacillus reuteri, co-evolved human bacterial strain derived from human breast milk, used for the prevention of Necrotizing enterocolitis (NEC); and IBP-1016, a drug candidate used for the treatment of gastroschisis, a severe disease in infants. The company develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal injury, necrosis, perforation in the intestinal tracts of infants and death. It operates through a network of neonatologists and research groups. IBT is headquartered in Stockholm City, Sweden.

Infant Bacterial Therapeutics AB Key Recent Developments

Feb 05,2019: Infant Bacterial Therapeutics names Anna Olsson as Director of Clinical Development

Nov 21,2018: The Phase 3 study protocol is modified after IBT's meeting with the FDA

Nov 14,2018: Infant Bacterial Therapeutics interim management statement, January 1-September 30, 2018

Sep 10,2018: TOPC : Nasdaq Stockholm Welcomes Infant Bacterial Therapeutics to the Main Market[Newswire : FS-GNW RSS]

Aug 16,2018: Infant Bacterial Therapeutics interim management statement, January 1-June 30, 2018

This comprehensive SWOT profile of Infant Bacterial Therapeutics AB provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData's 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Infant Bacterial Therapeutics AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

READ MORE

Scope

Table of Contents

Section 1-About the Company

Infant Bacterial Therapeutics AB-Key Information

Infant Bacterial Therapeutics AB-Overview

Infant Bacterial Therapeutics AB-Key Employees

Infant Bacterial Therapeutics AB-Key Employee Biographies

Infant Bacterial Therapeutics AB-Key Operational Heads

Infant Bacterial Therapeutics AB-Major Products and Services

Infant Bacterial Therapeutics AB-History

Infant Bacterial Therapeutics AB-Company Statement

Infant Bacterial Therapeutics AB-Locations And Subsidiaries

Infant Bacterial Therapeutics AB-Key Manufacturing facilities

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Infant Bacterial Therapeutics AB-Business Description

Infant Bacterial Therapeutics AB-Corporate Strategy

Infant Bacterial Therapeutics AB-SWOT Analysis

SWOT Analysis-Overview

Infant Bacterial Therapeutics AB-Strengths

Infant Bacterial Therapeutics AB-Weaknesses

Infant Bacterial Therapeutics AB-Opportunities

Infant Bacterial Therapeutics AB-Threats

Infant Bacterial Therapeutics AB-Key Competitors

Section 3-Company Financial Performance Charts

Infant Bacterial Therapeutics AB-Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Appendix

Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Note*: Some sections may be missing if data is unavailable for the company


List Of Figure

List of Figures

Infant Bacterial Therapeutics AB, Performance Chart

Infant Bacterial Therapeutics AB, Ratio Charts


List Of Table

List of Tables

Infant Bacterial Therapeutics AB, Key Information

Infant Bacterial Therapeutics AB, Key Ratios

Infant Bacterial Therapeutics AB, Share Data

Infant Bacterial Therapeutics AB, Major Products and Services

Infant Bacterial Therapeutics AB, History

Infant Bacterial Therapeutics AB, Key Employees

Infant Bacterial Therapeutics AB, Key Employee Biographies

Infant Bacterial Therapeutics AB, Key Operational Heads

Infant Bacterial Therapeutics AB, Other Locations

Infant Bacterial Therapeutics AB, Subsidiaries

Infant Bacterial Therapeutics AB, Key Manufacturing facilities

Infant Bacterial Therapeutics AB, Key Competitors

Infant Bacterial Therapeutics AB, SWOT Analysis

Infant Bacterial Therapeutics AB, Ratios based on current share price

Infant Bacterial Therapeutics AB, Annual Ratios

Infant Bacterial Therapeutics AB, Interim Ratios

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Infant Bacterial Therapeutics AB, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History, Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts